Home / World Marketplace / Archive by category Global Health & Biotech (Page 8)

Archive by category Global Health & Biotech

DataVault AI and Wellgistics Health Announce Plans for PharmacyChain™ to Implement Manufacturer-to-Patient Blockchain-enabled Smart Contracts for the Prescription Drug Industry to Improve Efficiency and Patient Outcomes

Strategic Alliance Targets Digital Transformation of the $634.32 Billion (1) U.S. Prescription Drug Market Through Blockchain-Enabled Data Monetization and AI-Driven Efficiency Gains BEAVERTON, Ore., Oct. 22, 2025 (Korea Bizwire) – via IBN – DataVault AI, Inc. (“DataVault”) (NASDAQ: DVLT), leading the way in AI data experience, valuation, and monetization, and Wellgistics Health, Inc. (“Wellgistics”) (NASDAQ: WGRX), a leader in [...]

Curia Sterile Drug Product Facility Named Massachusetts Manufacturer of the Year

ALBANY, N.Y., Oct. 21, 2025 (Korea Bizwire) – Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization, today announced its Burlington, MA sterile drug product facility has been named “Manufacturer of the Year” by the Massachusetts Legislative Manufacturing Caucus. The award was presented at the 10th Annual Manufacturing Awards Ceremony, held on [...]

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

Teva and Prestige announce a license and supply agreement for the commercialization of Prestige’s Tuznue®, a biosimilar to Herceptin® (trastuzumab) Tuznue® received European Commission (EC) marketing authorization in September 2024 Partnership brings together both companies’ expertise in biosimilars TEL AVIV, Israel, Oct. 20, 2025 (Korea Bizwire) – Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries [...]

KFSHRC Performs World’s First Robotic Intracranial Tumor Resection … A New Era in Neurosurgery

RIYADH, Saudi Arabia, Oct. 20, 2025 (Korea Bizwire) – In a historic leap for robotic medicine, King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riyadh has successfully performed the world’s first robotic intracranial tumor resection, a groundbreaking achievement that sets a new global standard in neurosurgical precision and recovery. The surgery was conducted on [...]

Boehringer’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC

Ingelheim, Germany / Ridgefield, Connecticut, U.S. Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC were presented for the first time at ESMO 2025. Confirmed response by blinded independent central review was 77%, with 96% of patients achieving disease control.1 Zongertinib recently received Breakthrough Therapy Designations for first-line treatment by the [...]

Junshi Biosciences Announces FDA’s Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients

SHANGHAI, Oct. 16, 2025 (Korea Bizwire) – Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the investigational new drug (“IND”) application for an open-label, two-arm, randomized, active-controlled, phase 2/3 clinical study comparing the company’s product, [...]

Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio

Collaboration and license agreement will advance Boehringer’s expanding antibody-drug conjugate (ADC) portfolio with a new asset expected to enter first-in-human studies next year. New, potentially best-in-class ADC is targeting a tumor selective marker present in a broad spectrum of cancers with high medical need. Ingelheim, Germany, and Seoul, Korea, 15 October 2025 – Boehringer Ingelheim and AimedBio, [...]

Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan

A Registrational Phase 2 clinical trial has been initiated for 64Cu-PSMA-I&T – a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells PARIS, Oct. 15, 2025 (Korea Bizwire) – Curium Group announced today that together with PeptiDream Inc. and PDRadiopharma Inc., a registrational Phase 2 clinical trial has been initiated in Japan for 64Cu-PSMA-I&T [...]

At COMPAMED, TekniPlex Healthcare to Showcase Interventional Design-to-Commercialization Services and Sustainability-Focused Materials Science Innovations.

Company to spotlight precision components, interventional device development, and bio-based material innovations to help OEMs meet ESG goals. Wayne, PA, Oct. 14, 2025 (Korea Bizwire) – TekniPlex Healthcare, which utilizes advanced materials science expertise to help deliver better patient outcomes, will showcase its dual focus on interventional design-to-commercialization capabilities and sustainability-driven materials science at COMPAMED 2025, taking place November 17–20 in [...]

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and non-small cell lung cancer. Data from the Phase 1 trial of ZW191 provide readthrough to Zymeworks’ broader ADC portfolio utilizing its novel bystander active topoisomerase-1 inhibitor payload, ZD06519. [...]